VBI
VBI Vaccines is a Massachusetts-based biopharmaceutical company that researches and develops novel vaccines for the treatment of cancer and infectious diseases.
Business Model:
Revenue: $396k
Employees: 11-50
Rankings
Industries / Tags:
Detailed VBI Information
Geographic Data
Address: 160 Second Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
post ipo debt
Raised Last:
$12M
Raised Total:$381M
Social
Metrics
2,310,119Website Global Rank
8,145Website Monthly Traffic
Twitter Followers
Description
VBI Vaccines is a Massachusetts-based biopharmaceutical company that researches and develops novel vaccines for the treatment of cancer and infectious diseases.
Contact Phone:
+16178303031
Contact Email:
VBI went public on 2/24/2012 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
2/24/2012
Ticker Symbol:
VBIV
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2018 | Post-IPO Equity | $42.9M | 8/2015 | Post-IPO Equity | $6.3M | 4/2020 | Post-IPO Equity | $57.5M | 8/2013 | Post-IPO Debt | $250k | 5/2020 | Post-IPO Debt | 1 | $50M |
K2 HealthVentures K2 HealthVentures K2 HealthVentures K2 HealthVentures |
12/2013 | Post-IPO Debt | $1.4M | 10/2017 | Post-IPO Equity | 1 | $71.9M |
Pontifax Pontifax |
9/2019 | Post-IPO Equity | $40.3M | 3/2013 | Post-IPO Debt | $751.1k | 5/2021 | Post-IPO Debt | 1 | $12M |
K2 HealthVentures K2 HealthVentures |
9/2022 | Post-IPO Debt | $100M |
K2 HealthVentures |
4/2020 | Post-IPO Equity | $1.1M | 12/2018 | Post-IPO Equity | $37.5M | 6/2013 | Post-IPO Debt | $750k | 7/2011 | Debt Financing | $3.5M | 9/2022 | Post-IPO Debt | 1 | $100M |
K2 HealthVentures K2 HealthVentures |
12/2016 | Post-IPO Equity | 1 | $10.6M |
Perceptive Advisors Perceptive Advisors Perceptive Advisors Perceptive Advisors |
7/2016 | Post-IPO Equity | $0 |
OPKO Health Perceptive Advisors ARCH Venture Partners OPKO Health OPKO Health Perceptive Advisors ARCH Venture Partners OPKO Health |
8/2014 | Post-IPO Equity | $11M | 3/2014 | Post-IPO Debt | $1.5M | 1/2007 | Series A | 3 | $35.7M |
Clarus Ventures ARCH Venture Partners 5AM Ventures Clarus Ventures ARCH Venture Partners 5AM Ventures |
12/2016 | Post-IPO Debt | 1 | $13M |
Perceptive Advisors Perceptive Advisors Perceptive Advisors Perceptive Advisors |
7/2012 | Post-IPO Debt | $1.2M | 2/2012 | Debt Financing | $2.2M | 11/2010 | Debt Financing | $4.3M | 7/2016 | Post-IPO Equity | 3 | $13.6M |
OPKO Health Perceptive Advisors ARCH Venture Partners OPKO Health OPKO Health Perceptive Advisors ARCH Venture Partners OPKO Health |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 5/2016 | SciVac Therapeutics | |
| 9/2011 | Epixis |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
